DK0603301T3 - Farmaceutisk præparat indeholdende et urikosurikon og en excitatorisk-aminosyre-antagonist - Google Patents

Farmaceutisk præparat indeholdende et urikosurikon og en excitatorisk-aminosyre-antagonist

Info

Publication number
DK0603301T3
DK0603301T3 DK92919882T DK92919882T DK0603301T3 DK 0603301 T3 DK0603301 T3 DK 0603301T3 DK 92919882 T DK92919882 T DK 92919882T DK 92919882 T DK92919882 T DK 92919882T DK 0603301 T3 DK0603301 T3 DK 0603301T3
Authority
DK
Denmark
Prior art keywords
amino acid
excitatory amino
acid antagonist
uricosuricon
pharmaceutical preparation
Prior art date
Application number
DK92919882T
Other languages
Danish (da)
English (en)
Inventor
Christopher Franklin Bigge
Charles Price Taylor Jr
Devin Franklin Welty
Graham Johnson
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Application granted granted Critical
Publication of DK0603301T3 publication Critical patent/DK0603301T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK92919882T 1991-09-09 1992-09-02 Farmaceutisk præparat indeholdende et urikosurikon og en excitatorisk-aminosyre-antagonist DK0603301T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75640191A 1991-09-09 1991-09-09
PCT/US1992/007540 WO1993004688A1 (en) 1991-09-09 1992-09-02 Pharmaceutical preparation containing an uricosuric and an excitatory amino acid antagonist

Publications (1)

Publication Number Publication Date
DK0603301T3 true DK0603301T3 (da) 1998-09-14

Family

ID=25043303

Family Applications (1)

Application Number Title Priority Date Filing Date
DK92919882T DK0603301T3 (da) 1991-09-09 1992-09-02 Farmaceutisk præparat indeholdende et urikosurikon og en excitatorisk-aminosyre-antagonist

Country Status (16)

Country Link
US (4) US5407935A (de)
EP (1) EP0603301B1 (de)
JP (1) JP3218038B2 (de)
AT (1) ATE162075T1 (de)
AU (1) AU660717B2 (de)
CA (1) CA2115442C (de)
DE (1) DE69224069T2 (de)
DK (1) DK0603301T3 (de)
ES (1) ES2113957T3 (de)
GR (1) GR3026369T3 (de)
MX (1) MX9205127A (de)
NO (1) NO307645B1 (de)
NZ (1) NZ244243A (de)
PT (1) PT100850B (de)
WO (1) WO1993004688A1 (de)
ZA (1) ZA926837B (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69224069T2 (de) * 1991-09-09 1998-07-02 Warner-Lambert Co., Ann Arbor, Mich. Pharmazeutisches kombinationspräparat, das ein uricosurisches mittel und einen excitatorischen aminosäure-antagonisten enthält
US5318985A (en) * 1991-12-20 1994-06-07 Merrell Dow Pharmaceuticals Inc. Potentiation of NMDA antagonists
US5854217A (en) 1992-09-28 1998-12-29 Bearsden Bio, Inc. Allosteric modulators of the NMDA receptor and their use in the treatment of CNS disorders and enhancement of CNS function
JPH07505908A (ja) * 1992-09-28 1995-06-29 マックセチーニ、マリア　ルイザ Ｎｍｄａ受容体のアロステリックモジュレーター
WO1998003189A1 (en) 1996-07-22 1998-01-29 Cognetix, Inc. Use of conantokins
CA2261568A1 (en) 1996-07-22 1998-01-29 University Of Utah Research Foundation Conantokins
US6277825B1 (en) 1996-07-22 2001-08-21 University Of Utah Research Foundation Use of conantokins for treating pain
IL125950A0 (en) * 1997-09-05 1999-04-11 Pfizer Prod Inc Methods of administering ampa receptor antagonists to treat dyskinesias associated with dopamine agonist therapy
EP1082113A2 (de) * 1998-05-26 2001-03-14 Peter Louis Carlen Zusammensetzungen und verfahren zur verminderung von behinderter mentaler funktion, gedächtnisschwund und zur verkürzung der erholungszeit nach der narkose bei zaügetieren
US6399574B1 (en) 2000-03-22 2002-06-04 University Of Utah Research Foundation Use of conantokins
DE60137635D1 (de) 2000-06-28 2009-03-26 Merck & Co Inc Verwendung von allopurinol zur behandlung von bluthochdruck
US7276514B2 (en) * 2002-05-15 2007-10-02 Charitable Leadership Foundation - Medical Technology Acceleration Program Pyrroloquinoline quinone drugs for treatment of cardiac injury and methods of use thereof
US20080051428A1 (en) * 2002-05-15 2008-02-28 Davis Paul J Pyrroloquinoline quinone drugs and methods of use thereof
US20040152694A1 (en) * 2003-02-04 2004-08-05 Istvan Kurucz Methods and compositions for treating inflammatory disorders of the airways
US20050209317A1 (en) * 2004-03-22 2005-09-22 Apkarian A V Method and compositions for treatment of chronic neuropathic pain
US8461223B2 (en) 2005-04-07 2013-06-11 Aspen Aerogels, Inc. Microporous polycyclopentadiene-based aerogels
ITFI20050083A1 (it) * 2005-04-29 2006-10-30 Univ Firenze Uso dell'acido chinurenico per la prevenzione e il trattamento dello shock
WO2006121995A2 (en) 2005-05-09 2006-11-16 Tap Pharmaceutical Products, Inc. Methods for treating nephrolithiasis
US9181486B2 (en) 2006-05-25 2015-11-10 Aspen Aerogels, Inc. Aerogel compositions with enhanced performance
EP2338492A1 (de) 2009-12-24 2011-06-29 Universidad del Pais Vasco Verfahren und Zusammensetzung zur Behandlung von Alzheimer
RU2013109380A (ru) 2010-09-10 2014-10-20 Такеда Фармасьютикалс Ю.С.А.,Инк. Способ сопутствующей терапии с применением теофиллина и фебуксостата
US10806711B2 (en) 2011-08-12 2020-10-20 University Of Cincinnati Method of treating acute decompensated heart failure with probenecid
CA2904671C (en) 2013-03-13 2022-08-30 University Of Cincinnati Treatment of a diastolic cardiac dysfunction with a trpv2 receptor agonist
US20170143681A1 (en) 2015-11-02 2017-05-25 Apkarian Technologies Llc Methods and compositions for treating pain
EP3427729A1 (de) * 2017-07-13 2019-01-16 Paris Sciences et Lettres - Quartier Latin Probenecid zur behandlung von epileptischen erkrankungen, störungen oder zuständen

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4812458A (en) * 1986-09-16 1989-03-14 A/S Ferrosan 6,7-disubstituted-2,3-dihydroxyquinoxaline compounds, pharmaceutical compositions thereof, and their use as neuroleptics
DK146787A (da) * 1987-03-23 1988-09-24 Ferrosan Heterocykliske forbindelser, deres fremstilling og anvendelse
DE69201141T2 (de) * 1991-02-28 1995-05-11 Merrell Dow Pharma NMDA-Antagonisten.
DE69224069T2 (de) * 1991-09-09 1998-07-02 Warner-Lambert Co., Ann Arbor, Mich. Pharmazeutisches kombinationspräparat, das ein uricosurisches mittel und einen excitatorischen aminosäure-antagonisten enthält

Also Published As

Publication number Publication date
GR3026369T3 (en) 1998-06-30
AU660717B2 (en) 1995-07-06
AU2594392A (en) 1993-04-05
ES2113957T3 (es) 1998-05-16
NO307645B1 (no) 2000-05-08
US5627168A (en) 1997-05-06
CA2115442C (en) 2003-09-23
PT100850B (pt) 1999-07-30
CA2115442A1 (en) 1993-03-18
ATE162075T1 (de) 1998-01-15
WO1993004688A1 (en) 1993-03-18
JP3218038B2 (ja) 2001-10-15
NZ244243A (en) 1995-07-26
NO940809D0 (no) 1994-03-08
US5407935A (en) 1995-04-18
ZA926837B (en) 1994-03-08
DE69224069D1 (de) 1998-02-19
JPH06510544A (ja) 1994-11-24
PT100850A (pt) 1993-10-29
US5767119A (en) 1998-06-16
US5942513A (en) 1999-08-24
NO940809L (no) 1994-03-08
EP0603301A1 (de) 1994-06-29
MX9205127A (es) 1993-07-01
DE69224069T2 (de) 1998-07-02
EP0603301B1 (de) 1998-01-14

Similar Documents

Publication Publication Date Title
DK0603301T3 (da) Farmaceutisk præparat indeholdende et urikosurikon og en excitatorisk-aminosyre-antagonist
PT705100E (pt) Guanidinas substituidas terapeuticas
DK46789D0 (da) 3-indolpyrodruesyrederivater og farmaceutisk anvendelse deraf
UA26213C2 (uk) Засіб для профілактики та лікуваhhя остеопорозу та фармацевтичhа композиція hа їх осhові
DE69200685D1 (de) Benzocyclobutyl- oder Indanyl-Alkyl-Amino-Alkyl substituierte 3-Benzazepin-2-ones, verwendbar in der Behandlung von kardiovaskularen Krankheiten.
EE03969B1 (et) (Metüülsulfonüül)fenüül-2-(5H)-furanoonid, nende kasutamine ja farmatseutilised kompositsioonid
ATE211384T1 (de) Verwendung von adenosinantagonisten zur vorbeugung und behandlung von pankreatitis und ulcera
ES2182903T3 (es) Derivados heterociclicos utiles en el tratamiento de enfermedades alergicas o reumaticas, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
ITMI931649A1 (it) Derivati dell'acido 2-ammino-4-fenil-4-osso butirrico
IT8720771A0 (it) Composizioni farmaceutiche per la prevenzione e terapia della calcolosi delle vie biliari e della dispepsia biliare.
EA200000242A1 (ru) Применение фанхинона для лечения болезни альцгеймера
ATE124681T1 (de) Arzneimittelzusammensetzungen zur behandlung von psoriasis.
NO993627L (no) Anvendelse av en forbindelse for fremstilling av et legemiddel
BR9812531A (pt) Combinação de componentes, preparação farmacêutica, produção desta, e, uso da combinação ou da preparação farmacêutica
NO880406L (no) 5-(3-alkyl-5-tert-butyl-4-hydroksyfenyl)-2-amino-6h-1,3,4-tiadiaziner, fremgangsmaate til deres fremstilling og legemidler som inneholder dem og deres anvendelse.
ATE82850T1 (de) Verwendung von 2-pyrimidinyl-1-piperazinderivaten.
FI914410A0 (fi) Kalciumupptagande inhibitorer.
ITMI911930A1 (it) Composizioni farmaceutiche di stereoisomeri di ossiracetam e loro impiego terapeutico.
EA199800575A1 (ru) Производные пиперазина
DE59405654D1 (de) T-lymphozyten enthaltende pharmazeutische zusammensetzung zur behandlung von infektionen
DK8893D0 (da) Medicament for treatment or prevention of disease
ATE103491T1 (de) Behandlung von arteriosklerosis durch verabreichung von l-tryptophane oder l-5hydroxytryptophan.